William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

BoC Interest Rate Decision (Jan.) The Bank of Canada cut its key interest rate by 50 basis points to 3.25%. The Bank Rate is ...

A daily rundown of the economic reports and corporate earnings that will be grabbing the market’s attention in the week ahead ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

In the latest market close, AbbVie (ABBV) reached $170.30, with a -0.22% movement compared to the previous day. This change was narrower than the S&P 500's 0.29% loss on the day. At the same time, the ...

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,026.90 today based on a ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.